Breast cancer remains a formidable adversary in the field of oncology, with radiotherapy serving as one of its most prevalent treatment modalities. Traditionally, radiotherapy is administered postoperatively to eliminate residual cancer cells and reduce the chances of relapse. Yet, the biological
In today's discussion, we have the pleasure of speaking with Ivan Kairatov, a seasoned Biopharma expert known for his profound insights into the tech and innovation driving the pharmaceutical industry. With extensive experience in research and development, Ivan is here to share his knowledge about
In the labyrinthine complexity of human anatomy, accessing deep-lying tumors or delicate organs demands extraordinary precision. Even the slightest miscalculation can lead to serious complications, such as puncturing a major artery or missing malignant tissue entirely. This reality raises pivotal
Ivan Kairatov, a highly respected expert in the Biopharma industry, delves into the groundbreaking findings surrounding PPP2R1A mutations in ovarian clear cell carcinoma (OCCC) and their implications for cancer treatment. With his deep understanding of biotechnology and innovation, Kairatov shares
In a notable milestone for cancer treatment, Johnson & Johnson's cutting-edge investigational system, TAR-200, has been accorded priority review status by the FDA. Specifically designed for high-risk non-muscle invasive bladder cancer (NMIBC) patients, this system marks a significant leap forward,
In 2025, scientists continue grappling with puzzles surrounding the γ-secretase enzyme. Known for its role in Alzheimer’s disease and cancer, understanding its function remains daunting—an elusive target in biomedical research. As artificial intelligence (AI) steps into the arena, could this
